EFO-27 Cells
USUSD$430.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | The EFO-27 cell line is a human ovarian carcinoma model derived from a moderately differentiated serous papillary adenocarcinoma. It was established from a solid omental metastasis in a patient with advanced-stage ovarian cancer. EFO-27 is part of a series of ovarian tumor-derived cell lines developed to explore the hormonal regulation of ovarian cancer cell proliferation. In early passages, EFO-27 was reported to be aneuploid, with a modal chromosome number exceeding 100, indicating a high degree of chromosomal instability, a common feature of high-grade serous ovarian carcinomas. EFO-27 cells display an epithelioid morphology in vitro and have been shown to form dome-like multicellular structures in monolayer culture, a phenotype sometimes associated with active ion transport and tight junction formation. In serum-free media, the proliferation of EFO-27 was stimulated by gonadotropic hormones, specifically human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH), suggesting that the cells retain functional hormone receptor signaling pathways. This responsiveness highlights the potential role of gonadotropin signaling in promoting tumor growth and progression in ovarian carcinoma and supports EFO-27 as a relevant model for studying hormone-driven mechanisms in ovarian cancer biology. EFO-27 has also been included in major multi-omics datasets, such as the Cancer Cell Line Encyclopedia (CCLE) and COSMIC, where its genomic profile contributes to drug sensitivity mapping and tumor subtype classification. These datasets provide additional layers of information, including gene expression, copy number alterations, and mutational landscape, positioning EFO-27 as a well-characterized resource for preclinical research in ovarian cancer. |
|---|---|
| 生物體 | Human |
| 組織 | Metastatic |
| 疾病 | Ovarian mucinous adenocarcinoma |
| 轉移部位 | Omentum |
| 同義詞 | EFO 27, EFO27 |
特徵
| 年齡 | 36 years |
|---|---|
| 性別 | Female |
| 族裔 | Caucasian |
| 細胞類型 | Epithelioid cells growing adherently as monolayer |
| 生長特性 | Adherent |
監管數據
| 引用 | EFO-27 (Cytion catalog number 305769) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_1192 |
生物分子資料
| 突變譜 | Mutation: PTEN, Simple, p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA), Heterozygous (Cosmic-CLP=906852), TP53, Simple, p.Arg273Cys (c.817C>T), Heterozygous (Cosmic-CLP=906852) |
|---|
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 20% FBS, additional 2.0 mM L-Glutamine, 1% NEAA, 1 mM sodium pyruvate |
| 解離試劑 | Accutase |
| 倍增時間 | 29 hours |
| 播種密度 | 1 to 3 x 104 cells/cm2 |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305769-070426 | 分析證明書 | 15. May. 2026 | 305769 |